FDA
-
-
-
-
-
-
-
Iovance Biotherapeutics to Present at Upcoming Conference
-
-
-
-
-
-
-
Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
-
-
-
-
-
-
-
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Barclays Reiterates Overweight Rating on Replimune Group (REPL), PT $17, 'We see this as a clear positive for Iovance's Amtagvi'
-
-
-
-
-
-
-
Scott+Scott Attorneys at Law LLP Alerts Investors of The Pending Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
-
-
-
-
-
-
-
Scott+Scott Attorneys at Law LLP Again Alerts Investors of The Pending Securities Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
-
322,966 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

